Delve Bio

San Francisco, United States Founded: 2022 • Age: 4 yrs
Sequencing platform is developed to detect neuro-infectious pathogens.

About Delve Bio

Delve Bio is a company based in San Francisco (United States) founded in 2022 by Bradley Murray.. Delve Bio has raised $35 million across 1 funding round from investors including Xontogeny, Google Ventures and S32. Delve Bio offers products and services including Delve Detect. Delve Bio operates in a competitive market with competitors including Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others.

  • Headquarter San Francisco, United States
  • Founders Bradley Murray
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Delve Llc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $35 M (USD)

    in 1 rounds

  • Latest Funding Round
    $35 M (USD), Series A

    Jun 20, 2023

  • Investors
    Xontogeny

    & 2 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Delve Bio

Delve Bio offers a comprehensive portfolio of products and services, including Delve Detect. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Metagenomic sequencing for comprehensive pathogen identification in infections

People of Delve Bio
Headcount 1-10
Employee Profiles 16
Employee Profiles
People
Timothy Blicharz
Senior Director Of Clinical Research
People
Bradley Murray
CEO And Co-founder
People
Amy Wong
Senior Director Of Marketing And Business Development
People
Jeff Field
Chief Commercial Officer

Unlock access to complete

Funding Insights of Delve Bio

Delve Bio has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series A round of $35 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $35.0M
  • First Round

    (20 Jun 2023)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2023 Amount Series A - Delve Bio Valuation Xontogeny
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Delve Bio

Delve Bio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Xontogeny, Google Ventures and S32. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Corporate backed venture capital fund investing in multiple sectors
Founded Year Domain Location
Life science startups are accelerated through focused programs by Xontogeny.
Founded Year Domain Location
Tech startups are funded by S32, a venture capital entity.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Delve Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Delve Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Delve Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Delve Bio

Delve Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Health risks are identified through online genetic and diagnostic testing.
domain founded_year HQ Location
Provider of diagnostic solutions for systemic infections
domain founded_year HQ Location
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
domain founded_year HQ Location
Genome sequencing diagnostics for infectious diseases are developed.
domain founded_year HQ Location
Provider of machine learning based diagnostic solutions for infectious diseases
domain founded_year HQ Location
Portable PCR diagnostics for infectious diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Delve Bio

When was Delve Bio founded?

Delve Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Delve Bio located?

Delve Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of Delve Bio?

Bradley Murray is the current CEO of Delve Bio. They have also founded this company.

Is Delve Bio a funded company?

Delve Bio is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series A of $35M, raised on Jun 20, 2023.

What does Delve Bio do?

Delve Bio was founded in 2022 and is headquartered in San Francisco, United States. A metagenomic next-generation sequencing (mNGS) platform is provided by the company for laboratories and clinicians. Infectious diseases, including bacterial, viral, fungal, and parasitic species, are diagnosed through this technology. Operations focus on neuro-infectious pathogen detection within the biotechnology sector.

Who are the top competitors of Delve Bio?

Delve Bio's top competitors include Visby Medical, Inflammatix and Prenetics.

What products or services does Delve Bio offer?

Delve Bio offers Delve Detect.

Who are Delve Bio's investors?

Delve Bio has 3 investors. Key investors include Xontogeny, Google Ventures, and S32.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available